Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/53168
Full metadata record
DC FieldValueLanguage
dc.contributor.authorXufang Dengen_US
dc.contributor.authorSarah E. St Johnen_US
dc.contributor.authorHeather L. Osswalden_US
dc.contributor.authorAmornrat O'Brienen_US
dc.contributor.authorBridget S. Banachen_US
dc.contributor.authorKatrina Sleemanen_US
dc.contributor.authorArun K. Ghoshen_US
dc.contributor.authorAndrew D. Mesecaren_US
dc.contributor.authorSusan C. Bakeren_US
dc.date.accessioned2018-09-04T09:44:32Z-
dc.date.available2018-09-04T09:44:32Z-
dc.date.issued2014-01-01en_US
dc.identifier.issn10985514en_US
dc.identifier.issn0022538Xen_US
dc.identifier.other2-s2.0-84907442809en_US
dc.identifier.other10.1128/JVI.01528-14en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84907442809&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/53168-
dc.description.abstract© 2014, American Society for Microbiology. Viral protease inhibitors are remarkably effective at blocking the replication of viruses such as human immunodeficiency virus and hepatitis C virus, but they inevitably lead to the selection of inhibitor-resistant mutants, which may contribute to ongoing disease. Protease inhibitors blocking the replication of coronavirus (CoV), including the causative agents of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), provide a promising foundation for the development of anticoronaviral therapeutics. However, the selection and consequences of inhibitor-resistant CoVs are unknown. In this study, we exploited the model coronavirus, mouse hepatitis virus (MHV), to investigate the genotype and phenotype of MHV quasispecies selected for resistance to a broad-spectrum CoV 3C-like protease (3CLpro) inhibitor. Clonal sequencing identified single or double mutations within the 3CLpro coding sequence of inhibitor-resistant virus. Using reverse genetics to generate isogenic viruses with mutant 3CLpros, we found that viruses encoding double-mutant 3CLpros are fully resistant to the inhibitor and exhibit a significant delay in proteolytic processing of the viral replicase polyprotein. The inhibitor-resistant viruses also exhibited postponed and reduced production of infectious virus particles. Biochemical analysis verified double-mutant 3CLpro enzyme as impaired for protease activity and exhibiting reduced sensitivity to the inhibitor and revealed a delayed kinetics of inhibitor hydrolysis and activity restoration. Furthermore, the inhibitor-resistant virus was shown to be highly attenuated in mice. Our study provides the first insight into the pathogenicity and mechanism of 3CLpro inhibitor-resistant CoV mutants, revealing a low genetic barrier but high fitness cost of resistance.en_US
dc.subjectAgricultural and Biological Sciencesen_US
dc.subjectImmunology and Microbiologyen_US
dc.titleCoronaviruses resistant to a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic barrier but high fitness cost of resistanceen_US
dc.typeJournalen_US
article.title.sourcetitleJournal of Virologyen_US
article.volume88en_US
article.stream.affiliationsLoyola University Stritch School of Medicineen_US
article.stream.affiliationsPurdue Universityen_US
article.stream.affiliationsPurdue University College of Scienceen_US
article.stream.affiliationsChiang Mai Universityen_US
article.stream.affiliationsUniversity of Chicago Medical Centeren_US
article.stream.affiliationsNational Center for Immunization and Respiratory Diseasesen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.